A disease caused by niacin (vitamin B 3 ) deficiency that has prominent neuropsychiatric symptoms.
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, their major impact is on morbidity: psychiatric disorders account for around one-third of disability worldwide 2 and cause enormous personal and societal burdens 3 . In the past century, considerable efforts towards understanding the nature of psychiatric disorders have been undertaken. There have been successes, and a few diseases (for example, pellagra 4 and neurosyphilis 5 ) with prominent psychiatric manifestations that were previously prevalent are now rare in many parts of the world. These few triumphs stand in contrast to decades of frustration and occasional notoriety, when highly publicized and plausible findings failed to be replicated. Indeed, most psychiatric disorders have been intractable to approaches that were fruitful in other areas of medicine. Thus, psychiatric syndromes are generally referred to as 'disorders' (which are illnesses that disrupt normal function), and only a few are referred to as 'diseases' (which are disorders with a known pathophysiology or structural pathology). An obvious goal of psychiatric research is to convert idiopathic disorders into pathophysiologically defined diseases.
Since 2007, numerous robust and replicable genetic findings have been reported for psychiatric disorders. These advances have mostly been through genome-wide association studies (GWASs) and structural variation studies, although studies of uncommon or rare exonic variation are likely to have a prominent role in the next few years. These results meet community standards in human genetics for significance and replication 6 . Although these findings often appear in high-profile journals, sentiments such as 'genetics has failed in psychiatry' or 'there are no genes for psychiatric disorders' are still heard. A review of psychiatric genetics is thus particularly opportune.
Over 300 psychiatric disorders have been described, and nine are covered in this Review. The conditions selected are all psychiatric disorders that have been subjected to intensive genetic study and for which genomewide results (usually GWASs and structural variation but also genome-wide linkage and resequencing) have been obtained. The disorders and their abbreviations are defined in TABLE 1 and Supplementary information S1  (table) , and the heritabilites and lifetime prevalences are depicted in FIG. 1a . Intellectual disability could have been included, but the voluminous literature on this topic has been thoroughly reviewed [7] [8] [9] . Studies of other psychiatric disorders are in progress, but the published data are few (for example, in the cases of obsessive-compulsive disorder, Tourette's syndrome and panic disorder).
The genetic dissection of complex traits has been frequently reviewed 6, [10] [11] [12] , so here we provide a brief overview of the approaches and study design considerations in BOX 1. Advances in genetics are often yoked to Genome-wide association studies (GWASs) . Unbiased genome screens of unrelated cases and appropriately matched controls or parent-affected child trios. The dominant technology has been individual genotyping using highly multiplexed SNP arrays.
Structural variation
A genomic alteration that changes the number of copies or the arrangement of the genome. Copy number variants are one type of structural variation.
Genome-wide linkage
A type of unbiased genome screen based on multiplex pedigrees. Genotyping approaches have included restriction fragment length polymorphisms, microsatellites and SNP arrays. After adjustment for multiple comparisons, the signal is the co-segregation of a genotype with a disease phenotype within the pedigrees.
Karyotyping
Determination of the microscopic appearance and gross changes in chromosomal content and structure of a cell.
Meta-analyses
These are methods for summarizing and combining results across multiple studies and are widely used in complex trait genetics. Meta-analyses combine the summary results from each study.
technological advancements. Major approaches that have been informative in psychiatric genetics include assessment of: structural variation through karyotyping, arraybased methods and high-throughput sequencing [13] [14] [15] [16] (TABLE 2 and Supplementary information S2 (table)); GWASs using highly multiplexed SNP arrays and, potentially, high-throughput sequencing 12, [17] [18] [19] (TABLE 3); and high-throughput sequencing to uncover rare variants of fairly strong effect (perhaps arising de novo) 20, 21 . Genome-wide linkage and hypothesis-driven candidate gene association studies have also been conducted but, as in many areas of biomedicine, with uncertain yield [22] [23] [24] [25] [26] . In this Review, we first summarize the literature for the nine disorders listed in TABLE 1 with a particular emphasis on the findings that appear to meet community standards for replication in human genetics (that is, robustly significant with consistent effects across samples) 6 . We then highlight new hypotheses that have emerged across the allelic spectrum, including de novo and rare exonic mutations, rare structural variation and common variation from GWASs. Crucially, these results provide empirical insights into the genetic architectures of these disorders: data that are essential for guiding future work in this area.
Alzheimer's disease Rare variation. Before 2007, rare autosomal dominant mutations in amyloid beta precursor protein (APP), presenilin 1 (PSEN1) and PSEN2 were known to cause early-onset familial Alzheimer's disease 27 . These loci have atypically large effect sizes, thereby facilitating identification using 'past generation' technologies, such as candidate gene association and genome-wide linkage studies (Supplementary information S2 (table)). Treatments for Alzheimer's disease based on these findings have been developed and are undergoing testing. Rare structural variation duplications containing APP have been associated with Alzheimer's disease 28, 29 . Small-exome sequencing studies of Alzheimer's disease have been published 30, 31 , and larger studies are in progress and should provide a more nuanced understanding of the role of rare exonic mutations in the pathogenesis of the disease.
Common variation.
In the early 1990s, apolipoprotein E (APOE) was identified by candidate gene association as a susceptibility gene for late-onset Alzheimer's disease, in no small part owing to its unusually large effect size 27, 32 (TABLE 3). In 2009, GWASs from two large consortia 33, 34 implicated three novel loci, and six additional loci were identified in 2011 (REFS 35, 36) . Full meta-analyses are keenly awaited, but the ten loci that have been identified to date account for ~20% of the total variation in risk or ~33% of the risk attributable to genetic effects, with the major contribution being from APOE. Note that the association of one gene identified by GWASs, complement component (3b/4b) receptor 1 (CR1), might result from structural variation 37 . 38 . Genes attaining genome-wide significance point towards immune and inflammatory processes (clusterin (CLU) and CR1), lipid processing (APOE, CLU and ABCA7) and endocytosis (phosphatidylinositol-binding clathrin assembly protein (PICALM), bridging integrator 1 (BIN1), CD2-associated protein (CD2AP) and CD33). Altered immune function and lipid metabolism had previously been proposed as Alzheimer's disease risk factors, but whether these represented causation or reverse causation was unclear 39 . The genetic findings now strongly point to reverse causation.
It is unclear how the above findings relate to accumulation of β-amyloid in Alzheimer's disease pathogenesis, but some relationship seems likely. For example, phosphatidylinositol-binding clathrin assembly protein (PICALM) and other endocytic molecules can modify Figure 1 | Results pertaining to genetic architecture. a | Plot of heritability by log 10 (lifetime prevalence) for the nine psychiatric disorders considered in this Review plus three complex diseases for which genetic dissection has been particularly successful (TABLE 1; Supplementary information S1 (table) ). Each disorder is plotted as heritability by lifetime prevalence. Colour indicates qualitative success in identifying aetiological genetic variation (with bright green meaning notably successful, dark green meaning some successes and red meaning minimal or no clear success to date). The bubble sizes are proportional to the numbers of cases studied in genome-wide association studies (GWASs; the smaller bubble indicates discovery number of cases (N case ), and the larger bubble indicates the total N case for discovery plus replication samples). b | Allelic spectrum of schizophrenia (SCZ). The inset is a conceptual schematic from a 2008 Nature Reviews Genetics article 10 . The lower part of the figure depicts empirical results for SCZ. The x-axis is log 10 (allele frequency (AF)) in controls. The y-axis is the point estimate for log 10 (genotypic relative risk (GRR). For clarity, confidence intervals are not shown. There are no known Mendelian variants for SCZ (AF << 0.0001, GRR >> 50). There are no known common variants (AF > 0.1) with GRR > 1.5, and these can be excluded with >99% statistical power. Nine structural variants associated with SCZ are shown as light blue diamonds (TABLE 2; 1q21.1-is the deletion and 1q21.1+ is the duplication). If AF in controls was 0, AF was set to 0.0001. These structural variants do not have a corresponding region in the inset. Seventeen common variants have been associated with SCZ (red circles; β-amyloid toxicity in yeast and other model systems 40 . Although these genetic findings provide support for novel causal relationships that could be targeted by treatments, the association data point to genomic regions, not genes. Moreover, the proximal steps from genotype to phenotype are unclear, and many of the implicated genes are plausibly involved in multiple relevant functions (for example, CLU is involved in altered immune function and lipid processing). figure) ). None is fully penetrant, and nearly all appear to be nonspecific, as risk is often increased for SCZ, autism spectrum disorder (ASD), developmental delay, intellectual disability, epilepsy, somatic dysmorphism and extremes of body mass and head size. Most of these structural variation regions are fairly large (hundreds of kilobases to hundreds of megabases) and generally centre on structural variation hotspots 42 . Two rare structural variants affect single genes (namely, neurexin 1 (NRXN1) and vasoactive intestinal peptide receptor 2 (VIPR2)) 43, 44 , offering opportunities for downstream functional studies. Pathway analyses of genes that are intersected by rare structural variants suggest enrichment for neuronal processes of plausible aetiological relevance (for example, postsynaptic signalling) [45] [46] [47] . The structural variation regions in TABLE 2 probably represent 'low-hanging fruit' , and more discoveries are likely when improved technologies for structural variation detection are applied to larger samples 15 . A complementary approach is to evaluate structural variation 'burden' in cases compared to controls (for example, the number of structural variants per person) 48, 49 . This approach tests an explicitly multigenic model whereby many rare but different genomic disruptions have an impact on disease risk. Increased structural variation burden in SCZ cases has been reported by multiple groups 47, 48, 50 . One report found more rare structural variation in SCZ cases (odds ratio = 1.15), particularly for large deletions (odds ratio = 3.6) 48 . De novo structural variants are also more common in SCZ cases 45 . For BIP, there are reports of increased [51] [52] [53] and similar structural variation burden in cases versus controls 54, 55 .
Psychotic disorders
De novo structural variation may be relevant in BIP (odds ratio = 4.8), particularly in cases with earlier ages of onset (odds ratio = 6.3) 53 . Multiple studies are now evaluating the role of de novo, rare and uncommon exonic variation in BIP and SCZ using resequencing or genotyping approaches. Two small-exome-sequencing studies 56, 57 reported rates of putatively functional mutations that exceeded null expectations in SCZ cases (although the rate of de novo point mutations was not elevated in cases, and specific genes were not identified). A recent study 58 conducted high-throughput sequencing on 166 cases with SCZ and
Box 1 | Study design considerations: simplex and multiplex
Study design is a crucial component of human genetics research. The major designs are case-control studies and pedigree-based studies. The most common design is the case-control study, in which the frequency of a genetic variant in those cases with a disorder is contrasted against the appropriate control group. Case-control designs are used in most genome-wide association studies (GWASs) 156 and next-generation sequencing studies, as they are efficient and conceptually straightforward 157 . Case-control studies are simpler, and most biases can be surmounted by careful study procedures, but they cannot delineate rare inherited variation from de novo variation. Family-based designs are more complex but can be used for association testing as well as for linkage evaluation of co-segregation of genotypes and phenotypes within pedigrees. They provide protection against a key form of bias (namely, population stratification artefacts) but are less efficient given that the unit of analysis is a set of relatives; however, it is possible to identify mutations that arise de novo.
An additional decision is whether to focus on the presence or absence of other affected family members (multiplex pedigrees and simplex pedigrees, respectively). Human genetic studies have classically focused on multiplex pedigrees under the assumption that these pedigrees are enriched for causal genetic variation with higher penetrance. A focus on multiplex pedigrees has led to the identification of specific mutations underlying hundreds of Mendelian disorders (including autism spectrum disorder (ASD) and Alzheimer's disease). Simplex pedigrees have become popular for ASD and schizophrenia (SCZ). Simplex-based ascertainment is tailored to evaluate de novo mutations and is predicated on a model in which disorder with dramatically reduced fecundity and a proven role of de novo structural variation might be explicable as a series of Mendelian disorders that can be attributed to recent high-penetrance mutations in any of a large number of genes.
However, this important choice is not simple, and it continues to be moderately controversial. Some investigators believe a focus on simplex pedigrees to be optimal, and other investigators have concerns about the implications of this decision. Some of the issues are listed below.
• Correct classification as simplex or multiplex requires confident knowledge of family history -many people either do not know their family psychiatric histories, true episodes of illness may have been kept private from other relatives, and some affected individuals can over-call illness in their relatives (for example, an individual with alcohol dependence labelling all relatives who drink as the same).
• Fecundity is a major confounder. If there are greater numbers of relatives, there is a greater chance of multiplex classification. In addition, the presence of a psychiatric disorder can reduce fecundity (for example, fecundity is reduced in SCZ, and having a child with ASD can be a powerful inducement not to reproduce further). If fecundity had not been inhibited because of a psychiatric disorder, some apparently simplex families might have been revealed to be multiplex.
• Simplex designs often require both parents. This complicates recruitment, increases genetic assay costs and becomes increasingly less practical for disorders with later ages of onset.
• Both designs have a hidden weakness in the possibility of enriching for environmental causes of illness. Many psychiatric disorders have multiple different but rare environmental risk factors that are sufficient to cause a disorder. These potent exposures are sometimes very difficult to detect or are not routinely evaluated. Examples include mercury poisoning and ASD or viral meningitis and SCZ. Contrary to its intent, simplex cases may be enriched for difficult-to-detect, individual-specific environmental causes. Multiplex ascertainment could enrich for shared environmental causes. Some recent data pertain to this choice. Unexpectedly, simplex and multiplex ASD pedigrees show fairly similar de novo mutation rates for structural variation 81, 82 and exonic variation [84] [85] [86] . It is possible that larger studies will find differences in de novo mutation rates between simplex and multiplex families but the magnitude is likely to be smaller than anticipated. For SCZ, the available data are insufficient to resolve this issue 45, 50 . It has also been pointed out that de novo events must confer risk in multiplex families, as such mutations increase the chance that an individual is affected and increase risk in that person's offspring. Intriguingly, there are three instances of ASD cases with de novo deletions of 16p11.2 who also had an affected sibling without this deletion [158] [159] [160] , along with similar observations for structural variants in 1q21.1 and 17p12 (REF. 159 ).
β-amyloid
Neuronal accumulation of this peptide contributes to the aetiology of Alzheimer's disease.
Multiplex pedigrees
Family constellations containing more than one affected individual.
Simplex pedigrees
Family constellations containing one affected individual. on 307 controls, followed by genotyping of over 5,000 variants in 2,617 independent cases and 1,800 controls (the cases were enriched for treatment resistance or strong family histories). No finding met genome-wide significance. Larger studies are ongoing and will aid understanding this area in 2012-2013.
Common variation. The Psychiatric Genomics Consortium (PGC) recently published mega-analyses for SCZ and BIP 59, 60 . In SCZ, 9,394 cases and 12,462 controls were combined in a single analysis, and the top 81 statistically independent loci from that analysis were then tested in over 8,000 cases. The mega-analysis identified seven significant loci (TABLE 3) . A sign test for consistency between the mega-analysis and the follow-up stage was highly significant, implying that many of the 81 top loci include true risk loci but that power was insufficient. For BIP, the discovery phase consisted of 7,481 cases and 9,250 controls with a follow-up of 34 statistically independent loci in around 4,500 cases. Two loci exceeded genome-wide significance (TABLE 3) . Similarly, a sign test between the discovery and follow-up results was highly significant, again suggesting insufficient power 60 . In BIP, the genome-wide significant association at calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C) deserves specific comment, given 
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Locations are US National Center for Biotechnology Information (NCBI) Build 37 and University of California, Santa Cruz (UCSC) hg19. The positions of these structural variants are denoted in Supplementary information S3 (figure) with yellow circles. For succinctness, the citations refer to the most comprehensive study rather than to an initial report. 'Genes' refers to the number from the UCSC Known Genes data set. ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; SCZ, schizophrenia. calcium sensor 62 . Therefore, a detailed investigation of brain calcium biology is warranted for both BIP and SCZ.
For SCZ, the strongest association is in the extended major histocompatability complex region (MHC region; chr6:27-33 Mb). The evidence for association is compelling, but high gene density and exceptionally high linkage disequilibrium complicate the identification of specific sequence variation. Although it is tempting to propose that the association supports long-standing hypotheses its mechanistic implications. Indeed, multiple voltage gated calcium channel subunits were among the top 34 loci followed up in the BIP GWAS. Calcium channels are a treatment for BIP and regulate neuronal excitability and multiple brain functions, including long-term potentiation and synaptic plasticity. Combined analysis of the PGC BIP and SCZ samples strengthened the association in the CACNA1C region. Further, results from SGENE+ 61 implicate neurogranin (NRGN), which may act as a
Odds ratio
Similar to genotypic relative risk: a measure of the change in risk associated with a genetic variant.
Mega-analyses
These are methods (that are less widely used than meta-analyses) for summarizing and combining results across multiple studies. Mega-analysis combines individual-level genotype and phenotype data from all subjects in each study.
Major histocompatibility complex region (MHC) . A region of approximately 3 Mb on human chromosome 6p22.1 that is exceptionally complex and has considerable importance to disease. It contains genes encoding cell surface molecules that are important to immunity and disease susceptibility and many other functions.
concerning roles in SCZ for intra-uterine infection, autoimmunity or even synaptic pruning (in which MHC genes have a role), this lack of precision renders such propositions speculative.
A novel association for SCZ is in Ensembl gene RP11-490G2.1, which encodes the primary transcript for the microRNA miR-137 (MIR137) 63 . Supporting the hypothesis that this association implicates MIR137, predicted targets of miR-137 were significantly enriched for smaller GWAS P values (P < 0.01), and four of the genes that achieved genome-wide significance contain verified miR-137-binding sites 64 . miR-137 is a key regulator of neuronal development with roles in neurogenesis and maturation 65, 66 and is highly expressed at synapses in the cortex and hippocampus 67 . Future studies of networks regulated by miR-137 offer the possibility of insights into SCZ pathophysiology.
GWASs of BIP and SCZ have been predominantly based on subjects of European ancestry, but there are increasing reports from other world ancestries 68, 69 . Although those findings do not yet provide additional pathophysiological insights, it is worth noting that a chromosome 8 locus found in an East Asian sample 68 has support in the PGC data set, suggesting that planned mega-analyses across world populations will be informative.
Some of the most intriguing findings for SCZ and BIP are from large sets of genetic markers 70 
. There are now replicated data that vulnerability to SCZ is influenced by common genetic variation in hundreds of different loci, and this vulnerability partially overlaps that for BIP 70 . Indeed, the large-scale impact of large numbers of common variants may be a general feature of human complex traits [71] [72] [73] [74] [75] [76] [77] [78] Autism spectrum disorder Rare variation. For ASD, there is a notably strong prima facie case for there being a cardinal role for rare variation. Karyotyping studies suggest that on the order of 5% of ASD cases have one of a large number of rare but fairly gross chromosomal abnormalities 14, 79 . In addition, ASD has been noted as a co-morbid feature of >100 single-gene Mendelian medical genetic syndromes 80 , although the penetrance and confidence of the clinical associations are variable. Indeed, ASD mutations with a high penetrance are exceptional (that is, Rett's syndrome mutations in methyl-CpG-binding protein 2 (MECP2) and cyclin-dependent kinase-like 5 (CDKL5)), and Mendelian diseases that are enriched for ASD have far less than complete penetrance (for example, fragile X syndrome and tuberous sclerosis) 79 . Analysis of structural variation has been a major focus in ASD research (TABLE 2; Supplementary information S3 (figure)). Implicated loci to date are generally rare and potent risk factors but are incompletely penetrant and are not specific to ASD. As these large events have an impact on the dosages of many genes, biological insight has been slow to emerge; however, pathway analyses of genes within structural variants do implicate neuronal processes of aetiological relevance [45] [46] [47] . Large structural variants are present in 5-10% of ASD cases, and the number of ASD structural variants could total 130-234 (REF. 81 ). There is also consistent evidence for increased structural variation burden in ASD 49, [81] [82] [83] . For example, 5.8% of ASD probands had ≥1 rare de novo structural variant versus 1.7% of their unaffected siblings (odds ratio = 3.5), and this difference was more pronounced for structural variants that intersected genes 81 . The 16p11.2 structural variant that is associated with ASD 198 ). Most associations that achieve this level of significance are secure, but some may ultimately prove not to be. Included are SNPs with P < 5 × 10 -8 that were evaluated in samples of a minimum of around 10,000 cases and 10,000 controls. Discovery sample sizes reflect the primary samples for which full genome-wide association studies (GWASs) were conducted. In most cases, discovery P values were > 5 × 10 -8 but met a threshold (typically 1 × 10 -5
) for inclusion in replication efforts. In some instances, simultaneous publications based on overlapping samples were considered to be 'discovery' studies. Where this occurred, providing samples of roughly equivalent sizes, the most significant primary GWAS findings are given, otherwise the largest discovery samples are favoured. For many studies, it was not possible to extract the exact sample size used for each locus, so the sample sizes above are approximate. P values and odds ratios are from the meta-analysis with the largest sample sizes. If two meta-analyses based on overlapping samples reported similar results, the 'discovery' study is cited. The genes that are nearest to each locus are provided, but aetiological variants are generally unknown, and it remains likely that some of the associations do not alter the function of the designated genes (for example, ITIH3-ITIH4, in which multiple correlated SNPs span many genes, and TCF4-CCDC68, in which statistically independent associations occur in TCF4 and closer to CCDC68). In the TCF4-CCDC68 example, it may be that both associations point to the same functional element, but it is also possible that independent aetiological variants occur in adjacent genes. For the schizophrenia loci attributed to REF. 195 , no discovery sample size is listed because the initial P values were modest, and as the authors conducted multiple follow-up analyses, there is no obvious discovery sample. For the major histocompatibility complex (MHC), the International Schizophrenia Consortium 70 is designated a discovery study, as it was the only primary GWAS for which genome-wide significance at the MHC was obtained. REF. 195 is cited for the meta-analysis at the MHC, as it reported the most significant MHC association 195 . The most significant SNP at the MHC across the two studies is not identical, and the one listed is taken from REF. 195 . Multiple statistically independent SNPs have been reported at the MHC 59, 186 . We note that genome-wide significance had been reported in bipolar disorder for ankyrin 3 (ANK3) (REF. 199 ) but not in a larger mega-analysis that included the same samples 60 .
Others have reported genome-wide significance for composite phenotype studies of ITIH3-ITIH4 (REF. 200 ) (but see REF. 201 ) and calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C) 202 but in samples smaller than required for inclusion in the above table. For alcohol consumption, the rs671 association was in East Asian samples. The alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B) locus was also associated with alcohol dependence. Nicotine consumption is measured in terms of maximal number of cigarettes smoked per day. Smoking initiation refers to ever versus never began smoking. Smoking cessation is whether regular smokers had quit at the time of interview. and SCZ has been termed a 'mirror image' structural variant, as the deletion and duplication are associated with increased and reduced head and body size. However, it is difficult to understand the clinical features of ASD and SCZ as mirror images, and more importantly ASD is associated with both 16p11.2 deletions and duplications.
ASD is the first psychiatric disorder for which exome sequencing using substantial numbers of samples has been published. Three recent papers describe the results from exome sequencing of ~600 trios and identify roles for de novo exonic mutations in sodium channel protein type 2 subunit alpha (SCN2A), katanin p60 subunit A-like 2 (KATNAL2) and chromodomain helicase DNA-binding protein 8 (CHD8) in the pathogenesis of ASD [84] [85] [86] . Intriguingly, all three studies noted an increased rate of de novo exonic mutations in older parents (with the mutations generally being of paternal origin) [84] [85] [86] , and pathway analyses reported in two of the studies found that genes containing de novo exonic variation were more closely connected in reference to protein-protein interaction databases 84, 85 . Additional sequencing studies are in progress.
However, a central finding from these papers was that only a minority of cases had a de novo putatively functional variant, suggesting that this class of genetic variation is unlikely fully to explain the clinical entity of ASD. Indeed, estimates from de novo exonic mutations (which are similar to those from structural variation data) suggest that ASD is highly polygenic (estimates ranged from 400-1,000 genes) 85, 86 . Importantly, a hypothetical model of ASD that it is caused by rare but fully penetrant mutations in 100 different genes could be confidently rejected 84 .
Common variation. Evaluation of rare structural variation and exonic variation in ASD is particularly advanced. By contrast, evaluation of common variation is far more limited (FIG. 1a) , and the published GWASs for ASD are small by current standards [87] [88] [89] [90] . It is currently not possible to discern or dismiss a role for common genetic variation in risk for ASD. In our opinion, GWASs with larger samples are needed for ASD, given that detailed studies of rare variation currently explain a fraction of risk and that common variation plays a clear part in other psychiatric disorders. Indeed, there were few confident findings for GWASs of SCZ when the sample sizes were similar to those that are now available for ASD. Additional support for our recommendation for more GWASs is provided by Voineagu et al. 91 , who identified a gene expression module that had attenuated expression in post-mortem brain samples of individuals with ASD and that also had enrichment for GWAS signals 91 .
Alcohol and nicotine dependence
Alcohol dependence (ALC) and nicotine dependence (NIC) are complex conditions to study, given the requirement for ingestion of a psychoactive substance and cohort effects due to temporal and geographic variation in the availability of ethanol and nicotine. Many investigators focus on ALC and NIC, which are clinically salient but multi-component syndromes 92 . As a part of the Tobacco and Genetics Consortium 93 , we determined
Box 2 | Pathway analysis
Pathway analysis is based on the assumption that risk variants for a disease will converge on sets of genes with functions that are more closely related to each other than to random sets of genes. For example, dominant forms of Alzheimer's disease are caused by mutations in amyloid beta precursor protein (APP), presenilin 1 (PSEN1) and PSEN2; the PSEN genes encode protein components of γ-secretase, a protease that cleaves APP. The availability of genome-wide association study (GWAS) and structural variation results for many psychiatric disorders, along with increasing amounts of sequence data, have generated interest in using analytic methods for exploiting nonrandom functional relationships between genes containing risk variants. Many approaches have been developed (for example, ALIGATOR 161 , INRICH 162 , DAPPLE 163 and GRAIL 164 ) and reviewed in detail elsewhere 147, 165, 166 . Although the algorithms differ, the principle behind these methods is to evaluate whether a given set of genomic regions (that is, a broadly inclusive definition of 'pathway') is enriched for genetic variants that show some relationship with disease compared to a null expectation.
There are important subsidiary considerations. The first is the definition of a 'pathway'. Standard pathways consist of sets of genes found in the Gene Ontology 167 , the Kyoto Encyclopedia of Genes and Genomes 168 or PANTHER databases 169 . Other pathway gene sets are manually curated by experts in a particular area (for example, genes that are known to make proteins that function at the synapse) 170, 171 . In addition, a 'pathway' can consist of genomic regions that are selected for a particular property, such as a high degree of conservation 172 or expression quantitative trait locus (eQTL) associations 173 . Finally, other pathways consist of genes that are known to be connected by experimental data (for example, by protein-protein interaction screens, microRNA target sites or gene expression modules).
It is advantageous that these pathway data sets are defined independently of genetic studies of psychiatric disorders, but they do have limitations and can contain errors of omission and commission. Standard gene sets can have highly overlapping pathways that complicate some analyses, and the pathway content can have variable quality. Expert-curated pathways can be more specific but can be vulnerable to post hoc bias (that is, including genes in a pathway on the basis of results from genetic studies). Pathways based on empirical approaches depend on the quality and completeness of the primary data (for example, existing protein-protein interaction databases cover the interaction space partially).
A second question concerns what is required before a member of a pathway is accepted as having some relationship with disease. For common variation, the analysis might be restricted to genes within recombination regions containing SNPs that have genome-wide significance, an approach that was used successfully to implicate broad biological pathways that are relevant to height 76 . However, much of the interest in pathway analysis involves exploiting much weaker associations under the assumption that these associations more reflect true associations in the context of limited power (signal) rather than chance (noise). If so, those weakly associated SNPs may also be nonrandom with respect to gene sets (BOX 3) . The threshold at which SNPs or genes are chosen is arbitrary, and the signal-to-noise ratio for a given arbitrary threshold can vary substantially with sample size and genetic architecture. For rare variants in complex diseases, in light of recent empirical results, pathway analysis will by necessity be based on sets of genes for which the involvement in disease is unclear (for example, genes with a single observed de novo exonic deleterious mutation) 84, 85 . A third consideration concerns the null expectation to which the observed pathways are compared. Early structural variant pathway analysis did not fully account for important biases, such as that large genes are more likely to be intersected by copy number variants by chance and that some functional pathways -often related to brain development -are enriched for large genes 164 . Early GWAS pathway analysis sometimes did not fully allow for the variable numbers of SNPs per gene and their degree of linkage disequilibrium, both of which have an impact on the probability of a high-ranking association 161 . Thus, it is necessary to be cautious about the use of pathway-based approaches. In psychiatric disorders, some results give cause for optimism 38, 45, 82 . Finally, in pathway analyses, the unit of inference is the pathway. Tempting although it may be, it is generally inappropriate to make strong inferences about specific variants or genes on the basis of their membership of pathways that attain some level of significance. It may be possible to do so if the variants or genes are subsequently evaluated in data sets independently of those from which the importance of the pathways are derived, using a statistical framework that adequately deals with multiple testing. 
Box 3 | Common variant risk profile
For schizophrenia (SCZ) and bipolar disorder (BIP), sign tests comparing the consistency of association tests from discovery genome-wide association studies (GWASs) and replication samples for sets of top signals are usually highly significant even if most loci do not meet genome-wide significance 59, 60, 174 . This implies that sample sizes are insufficient and that additional loci can be discovered in larger samples. Tests of the existence of large numbers of true but weakly associated variants have been conducted for SCZ, BIP and many other biomedical disorders.
In light of theoretical work by Visscher and colleagues 71 , one study used GWAS results as a discovery set (after removing correlated SNPs), and subjects in 11 independent test GWAS data sets were assigned risk profile scores (that is, the number of SCZ risk alleles weighted by their effect sizes in the discovery set). The mean risk profile scores for cases were compared to the mean scores for controls in these independent data sets. Panel a of the figure shows risk profile scores for extremely relaxed P value thresholds (P T < 0.1, 0.2, 0.3, 0.4 and 0.5, light to dark green bars). Risk profile scores were derived (after linkage-disequilibriumbased SNP pruning) from a discovery SCZ sample and then applied to three independent SCZ samples 174, 175 , two BIP samples 176, 177 and six non-psychiatric diseases 177 . In three independent GWASs, SCZ cases had significantly higher risk profile scores than controls. Remarkably, the same set of markers also discriminated BIP cases from controls, indicating substantial genetic contributions between SCZ and BIP. As an important test of specificity, the SCZ risk profile was not predictive of case status for any of six non-psychiatric diseases 177 . A recent paper evaluated risk profile scores in a trio sample and could exclude population stratification as an explanation 178 . The proportion of variance explained by the risk profile score increased with relaxation of the significance thresholds. This suggests that the discovery sample was insufficiently large to identify many true risk loci at even nominal levels of significance: adding more SNPs contributed more genetic signal than noise. This is partly a feature of sample size. Panel b of the figure shows a similar analysis based on a larger discovery sample, in which the proportion of variance explained is approximately double 59 , and instead of increasing with P T the proportion of variance reaches a plateau. If the sample size were truly adequate, the first P T bin would explain the greatest amount of variance, and relaxing P T would decrease the proportion of variation explained.
Finally, estimates from two different methods indicated that the risk profile component for SCZ contributes between one-quarter and one-third of the overall variance in liability to SCZ 70, 131 , a substantial fraction of the 65-81% heritability of SCZ 179, 180 . These estimates suggest that 'missing heritability' is merely hidden and imperfectly assayed by current genotyping technologies. CAD, coronary artery disease; CD, Crohn's disease; HT, hypertension; MGS-AA, Molecular Genetics of Schizophrenia -African American; MGS-EA, Molecular Genetics of SchizophreniaEuropean American; RA, rheumatoid arthritis; STEP-BD, Systematic Treatment Enhancement Program for Bipolar Disorder; T1D, type 1 diabetes; T2D, type 2 diabetes; WTCCC, Wellcome Trust Case Control Consortium.
Panel a of this figure is modified, with permission, from 
Polygenic
Meaning 'many genes' . As a description of genetic architecture, polygenic gives no indications about the frequencies, modes of action or effect sizes of any relevant genetic variation.
that the components of the Fagerstrom test for nicotine dependence (which is a measure of NIC) had heritabilities ranging from fairly high to near zero with important common environmental effects. Other investigators evaluated self-reported lifetime maximum use of ethanol (measured in grams per day) or nicotine (measured in number of cigarettes per day), and such continuous measures of consumption are often available for secondary analysis of samples studied for other diseases.
For ALC, the published GWASs are small, and no large-scale meta-analysis has been conducted [94] [95] [96] [97] [98] . In our opinion, there are clear needs for a high-quality metaanalysis and for increasing the number of samples with GWAS data -particularly given that risk profile analysis (BOX 3) suggested that larger samples would yield more associations 98 . For alcohol consumption, GWASs in East Asian samples confirmed the role of aldehyde dehydrogenase 2 (ALDH2) 99, 100 , and autism susceptibility candidate 2 (AUTS2) was implicated in alcohol consumption in European subjects 101 . Using a candidate gene approach, the association of alcohol dehydrogenase 1B (ADH1B) with ALC and alcohol consumption was extended to European ancestry subjects 102 . For NIC, a field-wide meta-analysis is also needed. For smoking behaviour, large meta-analyses have been conducted 93, 103, 104 . The strongest finding is an association of smoking quantity with a cluster of nicotinic receptor genes (CHRNA5-CHRNA3-CHRNB4) with an effect size that corresponds to one cigarette per day, and there may be several independent associations 105 . Associations to this region have also been reported for lung cancer 106, 107 . A recent study showed that Chrna5-null mice had higher nicotine intake owing to loss of an inhibitory effect on brain reward systems 108 .
Major depressive disorder
The PGC GWAS mega-analysis of 9,240 major depressive disorder (MDD) cases and 9,519 controls (replication in 6,783 MDD cases) revealed no findings of genomewide significance 109 . These null results are intriguing, as almost all other published GWASs with N > 11,000 for any disease have found at least one genome-wide significant finding. The most likely reasons for these results are particularly high heterogeneity of MDD and insufficient power arising from its lower heritability 109 . There are few published data on structural variation, although one study found increased structural variation burden in MDD cases versus controls (odds ratio = 1.31) 110 . A provocative finding from 2003 was that risk for MDD might be influenced by a gene-environment interaction with genetic variation near the serotonin transporter 111 . Meta-analyses have supported 112, 113 and not supported 114, 115 this finding. This association did not replicate in an independent but similar study from the same geographic region, casting particular doubt on the reported association 116 .
Other disorders
The published GWASs for attention-deficit hyperactivity disorder (ADHD) 117 and anorexia nervosa 118 are small, but studies using larger sample sizes are currently in progress (for example, by the Wellcome Trust CaseControl Consortium for anorexia nervosa). Given low power, no conclusions about common variation can be made. In ADHD, increased structural variation burden has been reported (odds ratio = 2.1) 119, 120 , an effect that is higher in ADHD cases with intellectual disability (odds ratio = 5.7) 119 . Pathway analysis in ADHD found association signals enriched in the same Gene Ontology categories also overrepresented for large structural variants 121 . The weak signals in ADHD GWASs are not randomly distributed but index the same pathophysiological pathways as rare structural variants. Thus, it appears that the reason no common variants are yet to be confidently implicated in ADHD by GWASs is a lack of power and not a lack of variants to be found.
What is the emerging picture? Knowledge of psychiatric genetics is vastly greater than it was 5 years ago. Specifically, there are now multiple high-confidence structural variants (TABLE 2) , rare exonic variants (currently only for ASD, Alzheimer's disease and ALC) and an increasing number of robustly significant and replicated common variants (TABLE 3) . The data support multiple novel biological hypotheses -for example, cholesterol metabolism and the innate immune response in Alzheimer's disease, a network involving miR-137 for SCZ, calcium signalling for BIP and SCZ, and chromatin remodelling for ASD -and reinforce previous hypotheses, such as synaptic biology for SCZ and ASD.
Genetic architecture. These results also provide insights into genetic architecture that are crucial for planning more complete attempts at the genetic dissection of these major public health conditions. We can now make informed predictions about the types of future studies that can increase understanding in order to generate well-grounded biological hypotheses.
For several disorders, there are now data to replace the interminable debate about the fundamental nature of these illnesses 122 . These occasionally vociferous debates 71 have generally been of an 'either/or' nature: psychiatric disorders as collections of Mendelian-like, singlegene disorders (multiple rare variant models) 'versus' psychiatric disorders as caused by many common variants of small effects (common disease-common variant models) 15, 123 . Although we were initially agnostic 124 , we now believe that the data support both positions.
For disorders with sufficient data (Alzheimer's disease, BIP and SCZ), the results are consistent with an allelic spectrum and an aetiological role for both rare and common variation. As an example, FIG. 1b synthesizes current knowledge of SCZ as an empirical allelic spectrum map compared with a conceptual schematic from a 2008 Review in this journal 10 . There are no known Mendelian variants, and power analyses can exclude common variants of modest effect (genotypic relative risk >1.5 for allele frequencies >0.1). There are multiple structural variants that are rare, strong but nonspecific risk factors (TABLE 2) , and there are 17 common variant associations of subtle effects (TABLE 3) . There is an important component arising from common variation in hundreds of Prodrome Premonitory symptoms. In this case, a collection of psychotic symptoms that sometimes evolves into schizophrenia or a mood disorder or that resolves without further sequella. different loci
, and larger sample sizes are likely to convert many of these to genome-wide significance. The frequency region between 0.001 and 0.05 is under investigation by studies that evaluate exon variation, and more should be known in 2012-2013. Early data for ASD and SCZ suggest that this will not necessarily yield a treasure trove of new findings. At the very least, the 'many Mendelian model' seems to be extremely unlikely. This allelic spectrum map might well be replicated for other psychiatric disorders should larger studies of both rare, uncommon and common variation be achieved.
Hypothesized genetic architectures that consist entirely of rare variants are inconsistent with the data for Alzheimer's disease, ASD, BIP and SCZ (as well as for multiple other complex biomedical diseases) [71] [72] [73] [74] [75] [76] [77] [78] . The Procrustean theory that common variant signals inevitably reflect 'synthetic associations' 125 to rare, high-penetrance mutations is not credible 78, [126] [127] [128] . Psychiatric disorders are polygenic. The evidence is strong that many genes are involved in the aetiology of Alzheimer's disease (currently evidence of rare exonic, rare structural variation and common variation), ALC (currently evidence of common variation), ASD (currently evidence of de novo exonic variation and structural variation), BIP (currently evidence of common variation), NIC (currently evidence of common variation) and SCZ (currently evidence of rare structural variation and common variation). Projections for ASD and SCZ suggest that variation at hundreds of different genes will ultimately be shown to be involved 59, 81, 86 . There are statistical hints that ADHD and MDD might also be polygenic.
Polygenicity may be a general feature of complex biomedical diseases 129, 130 . Common variant SNP effects have been estimated to explain large proportions of the phenotypic heritability for a wide range of diseases: BIP and SCZ 70, 131 ; type 1 diabetes mellitus (T1DM), T2DM, Crohn's disease, rheumatoid arthritis, coeliac disease and coronary artery disease 71, 78 ; and continuous traits (namely, height, intelligence and body mass) 71, 132, 133 . These results are consistent with suggestions that the 'missing heritability' 134 is merely hidden 133 . As discussed further below, currently we do not now possess a comprehensive enumeration of loci that are associated with any psychiatric disorder (that is, the 'parts list'), regardless of where genetic variation might lie in the allelic spectrum-effect size space.
Implications and future directions Why these successes matter. As other commentators have written 71, 129, 135, 136 , and as we argued in early 2009 (REF. 124 ), the proximal purpose of genetic studies is to gain insight into biology. This goal is crucial for psychiatric disorders as so little is known about pathophysiology, and as highly publicized but ultimately false leads have occurred. For this primary goal, there have been unequivocal successes for many psychiatric disorders. This crucial point is sometimes overlooked: the knowledge base in psychiatric genetics is vastly greater than it was 5 years ago, and the rate of change is unprecedented in the history of the field.
What about clinical utility? So-called personalized medicine has been touted as the crucial yardstick against which to measure the success of genetic studies. We believe clinical utility is the ultimate goal but is an inappropriate proximal goal. Still, there are a number of findings for which clinical importance should be evaluated. For example, structural variant testing is often a part of the clinical evaluation of ASD, and careful evaluation of its use in psychosis is warranted. As another example, Perlis and colleagues are undertaking clinical trials on the 'repurposing' of isradipine (an approved antihypertensive that interacts with the protein product of CACNA1C) for the treatment of BIP. It is possible that risk profile scores, structural variant burden or rare variant burden could have clinical utility. If these assess latent liability, they might be useful in selected clinical scenarios (for example, for predicting which patients require aggressive treatment in the psychosis prodrome) 137 . The polygenicity of psychiatric disorders poses intriguing difficulties: how can these many genes be coherently tied together? A parsimonious hypothesis is that the polygenic basis of a psychiatric disorder is manifested in the regulation or function of one or more known or novel pathways. Genetic variation at many different loci could introduce numerous slight alterations that result in a pathway that is insufficiently robust in response to an environmental insult or that leads to an inappropriate developmental programme 138 . Risk for a complex psychiatric disorder could be conferred by the emergent properties of the pathway itself rather than any single component. For SCZ, this conceptualization is supported by the risk profile findings for SCZ and by the miR-137 results that hint at an underlying regulatory network. For ASD, typical patterns of cortical gene expression in frontal and temporal cortex have been found to be attenuated in ASD cases compared with controls, and an empirically derived gene expression module that is under-expressed in ASD was found to be enriched for known ASD susceptibility genes and genetic association signals 91 . Alternative modes of investigation, such as network medicine, are needed to further our understanding of the roles of pathways in complex biological traits 139 . If polygenicity is indeed fundamental to complex psychiatric disorders and if some psychiatric disorders eventually prove to be pathway diseases 138 , then we need to confront this directly and to develop innovative methods. Developing such methods is more constructive and more likely to advance our understanding of these devastating diseases than raging against nature for not delivering common diseases in simpler Mendelian units.
Indeed, if one or more psychiatric disorders eventually prove to be pathway diseases, there could be clinical benefit. We conjecture that it might be considerably easier to coax an existing but dysfunctional biological pathway into the normal range than to replace components that have been broken by Mendelian mutations. Moreover, in an era in which many drug companies have moved away from drug development for psychiatric disorders 140 , the ability to measure such a hypothetical pathway in an appropriate cellular system could enable chemical biology screens of existing and novel compounds, as well as the evaluation of the rational use of multiple compounds simultaneously.
Implications for strategy. A comprehensive portrait of genetic architecture does not now exist for any psychiatric disorder. Gaining a more complete knowledge of the 'parts list' for each disorder -the specific loci that are aetiologically involved plus the identity, frequency and impact of genetic variation at each locus -would be of exceptional importance. Such an enumeration would catalyse an array of specific, targeted and nuanced scientific studies. For example, such studies might lead to the elucidation of biological mechanisms between the genotype and psychiatric phenotype, enablement of cell-based chemical biology and pharmacological screening, evaluation of gene action over developmental time, addressing the important roles of gene-gene and gene-environment interactions, understanding the part played by epigenetic modifications, evaluation of disease prediction models, and so forth. This is an attainable goal. The genomic search space is large but finite and so, in theory, elucidating the parts list for a psychiatric disorder could be achieved. On the basis of the evidence acquired to date, thorough and well-powered genomic evaluations across the allelic spectrum are needed. We believe that a balanced portfolio of genomic assessments is required, as there are clear roles for common variation, structural variation, rare variation and de novo variation for most disorders. Most discoveries in psychiatric genetics to date are from GWASs and structural variant evaluation (both of which are often based on the use of GWAS chips), and larger and more comprehensive GWAS and structural variation studies are highly likely to increase knowledge 136 . It is possible to provide realistic estimates of power and to predict the number of new associations for each increment in sample size 129, 130, 141 (for example, predictions have been made for GWASs and structural variation studies in 50,000 SCZ cases and 50,000 controls 141 ). In light of the recent ASD studies, sequencing that is directed at rare and de novo variation will have a role in a balanced portfolio of approaches [84] [85] [86] . Indeed, with improvements in accuracy, coverage and pricing, it is possible that sequencing could evolve into the technology of choice for genotyping all major classes of genetic variation.
Such a series of studies would be costly, so a crucial challenge is funding. These costs deserve to be placed in the context of the public health implications of these disorders, and historically psychiatric research has been underfunded in comparison to public health impact (with the possible exception of Alzheimer's disease) [142] [143] [144] [145] . For example, the lifetime cost per person with SCZ is on the order of US$1.4 million 146 : if this program of research were eventually able to prevent only several dozen cases, it would probably prove to be cost-effective.
Continued cooperation. The successful study of any type of genetic variation in complex biomedical diseases requires large sample sizes as a means to cut the Gordian knot posed by genetic architecture, aetiological complexity and phenotypic uncertainty. To achieve this end, there have been multiple meta-analysis 147, 148 consortia in psychiatric genetics, of which the PGC is the largest and most encompassing 124, 149, 150 . Indeed, a GWAS co-authorship network graph shows the high connectedness of researchers in the field (Supplementary  information S4 (figure) ).
An initial concern regarding GWAS meta-analysis was that increased signal from combining multiple samples would be negated by 'noise' owing to inter-site differences. This theoretical concern has not been borne out in practice, as shown above with the examples in SCZ 59 , BIP 60 , smoking behaviour 93 , alcohol consumption 101 and Alzheimer's disease 35, 36 . These meta-analyses are designed to identify risk or protective loci that have fairly similar effects across populations and that are not particularly sensitive to sample-specific factors. For example, T2DM and breast cancer loci identified in European samples tend to be replicated in samples of East Asian ancestry 151, 152 . It is possible that some genetic variants associated with phenotype risk are only found in certain population groups and are missed in meta-analysis; however, conclusive identification of such loci is likely to be challenging unless the effect sizes are fairly large.
Statistical rigour. In our opinion, a key ingredient of progress in psychiatric genetics has been uncompromising statistical rigour. Genomic technologies routinely posit 10 5 -10 8 hypotheses, and false positives are a serious concern. For some investigators, suggestive statistical evidence combined with intriguing biology is sufficient. However, we fear that any benefit from relaxing statistical standards will be outweighed by the negative consequences of false-positive claims.
This issue is particularly salient for exonic variation. Humans carry a huge pool of phenotypically neutral background variation that adds noise to genetic analyses (for example, each person has ~100 loss-of-function variants, most of which are rare in a population) 153, 154 , and the presence of such variation complicates identification of disease-relevant variants. Thus, owing to chance, a researcher would expect to find a functional exonic mutation -possibly in a gene with intriguing biology -in one case sample and in none of their control samples. More quantitatively, if 1% of cases are caused by fully penetrant mutations in a single gene with no background confounding variation, then observing 10 deleterious mutations in 1,000 cases and 0 deleterious mutations in 1,000 controls would not stand out in test statistics from 20,000 genes. More realistic scenarios (including locus heterogeneity, incomplete penetrance and background variation) will substantially erode the signal. The published results for ASD [84] [85] [86] and unpublished data on SCZ suggest that these issues will be important and will underscore the need for sequencing studies to have the same emphasis on statistical rigour and large sample sizes that has enabled GWASs to realize success for multiple psychiatric disorders 155 
.
Psychiatric genetics is not 'post-genomic'. In psychiatric genetics, we are at the end of the beginning, not the beginning of the end. Remarkably, in a field that is characterized by a checkered history and few confident aetiological clues, the genetics knowledge base has advanced considerably during the past 5 years, and results to date contain clear indications that further study will yield greater insight. Elucidation of the genetic architectures of psychiatric disorders is an attainable goal with existing technologies (albeit that are both costly and cost-effective). Few predictions are perfectly safe, but we would argue that genetics is a particularly good bet for psychiatry.
